智通财经APP获悉，高盛发布研报称，巨子生物(02367)去年下半年业务继续超出预期，将其2025至2027财年净利润预测微调不足1%，目前料今年销售及净利润同比增长28%与24%，至71亿及25.5亿元人民币。该行对其目标价由64港元上调至72港元，重申“买入”评级。
报告显示，公司销售及净利润各同比增长56%与38%，超过该行预期8%与2%，并较市场预期高9%及5%。去年收入与净利润分别同比升57%及42%，亦均超出管理层的最新指引，分别高出该行预测4%和1%，及较市场预期高5%与3%。该行认为公司派息率达60%带来正面惊喜，意味着股息率达2%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.